Helena Foulkes
CIK 1429996 · EVP & President-CVS Pharmacy · last filed 2026-10-26
Helena Foulkes is an EVP & President-CVS Pharmacy who has filed 64 SEC Form 4 insider transactions across 5 companies since 2008. The most recent filing, for COST, was dated Oct 26, 2026. Across all open-market trades the lifetime net is −$26.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $7.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CVS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
ISSAQUAH, WA 98027
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| COST | Director | 1,359 | $1012.28 | $1.38M | $0 | 5 | 2026-10-26 |
| SKIL | Director | 13,750 | $4.75 | $65.3K | $0 | 6 | 2026-07-02 |
| Skillsoft Corp. (SKIL.WS) Delisted | Director | 200,000 | $0.01 | $1.3K | $0 | 4 | 2023-07-24 |
| HD | Director | 313 | $329.20 | $103.0K | $25.0K | 9 | 2021-05-24 |
| CVS | EVP & President-CVS Pharmacy | 69,143 | $90.25 | $6.24M | -$26.61M | 40 | 2018-02-21 |
Recent Filings
64 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-26 | COST | Grant (A) | +266 | $0 | EDGAR |
| 2026-07-02 | SKIL | Grant (A) | — | $0 | EDGAR |
| 2026-06-26 | SKIL | Exer (M) | — | $0 | EDGAR |
| 2026-03-27 | SKIL | Grant (A) | — | $0 | EDGAR |
| 2025-10-24 | COST | Grant (A) | +286 | $0 | EDGAR |
| 2025-07-18 | SKIL | Exer (M) | — | $0 | EDGAR |
| 2024-10-24 | COST | Grant (A) | +303 | $0 | EDGAR |
| 2024-07-23 | SKIL | Grant (A) | — | $0 | EDGAR |
| 2024-07-22 | SKIL | Exer (M) | +3,750 | $0 | EDGAR |
| 2024-01-12 | COST | Grant (A) | +8 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.